[go: up one dir, main page]

EA200401506A1 - Рекомбинантный поксвирус, экспрессирующий гомологичные гены, встроенные в поксвирусный геном - Google Patents

Рекомбинантный поксвирус, экспрессирующий гомологичные гены, встроенные в поксвирусный геном

Info

Publication number
EA200401506A1
EA200401506A1 EA200401506A EA200401506A EA200401506A1 EA 200401506 A1 EA200401506 A1 EA 200401506A1 EA 200401506 A EA200401506 A EA 200401506A EA 200401506 A EA200401506 A EA 200401506A EA 200401506 A1 EA200401506 A1 EA 200401506A1
Authority
EA
Eurasian Patent Office
Prior art keywords
poxvirus
expressing
homological
genes
integrated
Prior art date
Application number
EA200401506A
Other languages
English (en)
Other versions
EA012160B1 (ru
Inventor
Пол Хаули
Соня Лейрер
Original Assignee
Бавариан Нордик А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бавариан Нордик А/С filed Critical Бавариан Нордик А/С
Publication of EA200401506A1 publication Critical patent/EA200401506A1/ru
Publication of EA012160B1 publication Critical patent/EA012160B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Данное изобретение относится к рекомбинантному поксвирусному вектору, способному экспрессировать две или более гомологичных чужеродных последовательности, которые получены из разных вариантов микроорганизма и которые имеют гомологию 50% или выше. Изобретение, кроме того, относится к способу получения такого рекомбинантного поксвируса и применению указанного рекомбинантного поксвируса в качестве лекарственного средства или вакцины. Кроме того, предлагается способ воздействия, предпочтительно индуцирования иммунного ответа в существующем животном, включая человека.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200401506A 2002-05-16 2003-05-14 Рекомбинантный поксвирус, экспрессирующий гомологичные гены, встроенные в поксвирусный геном, и его применение EA012160B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200200752 2002-05-16
DKPA200200753 2002-05-16
PCT/EP2003/005047 WO2003097846A1 (en) 2002-05-16 2003-05-14 Recombinant poxvirus expressing homologous genes inserted into the poxviral genome

Publications (2)

Publication Number Publication Date
EA200401506A1 true EA200401506A1 (ru) 2005-04-28
EA012160B1 EA012160B1 (ru) 2009-08-28

Family

ID=29551228

Family Applications (3)

Application Number Title Priority Date Filing Date
EA200401506A EA012160B1 (ru) 2002-05-16 2003-05-14 Рекомбинантный поксвирус, экспрессирующий гомологичные гены, встроенные в поксвирусный геном, и его применение
EA200401507A EA007811B1 (ru) 2002-05-16 2003-05-14 Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva)
EA200900180A EA020230B1 (ru) 2002-05-16 2003-05-14 Рекомбинантный модифицированный вирус осповакцины анкара (mva), экспрессирующий гомологичные последовательности, встроенные в поксвирусный геном, и его применение

Family Applications After (2)

Application Number Title Priority Date Filing Date
EA200401507A EA007811B1 (ru) 2002-05-16 2003-05-14 Межгенные области, используемые в качестве инсерционных сайтов в геноме модифицированного вируса коровьей оспы анкара (mva)
EA200900180A EA020230B1 (ru) 2002-05-16 2003-05-14 Рекомбинантный модифицированный вирус осповакцины анкара (mva), экспрессирующий гомологичные последовательности, встроенные в поксвирусный геном, и его применение

Country Status (22)

Country Link
US (14) US7338662B2 (ru)
EP (3) EP2253709B1 (ru)
JP (4) JP4895505B2 (ru)
KR (4) KR101138067B1 (ru)
CN (6) CN102719408A (ru)
AT (1) ATE315660T1 (ru)
AU (4) AU2003242540A1 (ru)
BR (2) BRPI0311178B8 (ru)
CA (3) CA2812019A1 (ru)
DE (1) DE60303218T2 (ru)
DK (2) DK1506301T3 (ru)
EA (3) EA012160B1 (ru)
ES (1) ES2256776T3 (ru)
IL (4) IL164172A0 (ru)
MX (2) MXPA04010713A (ru)
NO (3) NO334273B1 (ru)
NZ (2) NZ536501A (ru)
PL (2) PL218318B1 (ru)
PT (1) PT1407033E (ru)
SI (1) SI1407033T1 (ru)
UA (1) UA82479C2 (ru)
WO (2) WO2003097845A1 (ru)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4101327C1 (ru) * 1991-01-18 1991-10-24 Mercedes-Benz Aktiengesellschaft, 7000 Stuttgart, De
AU3163902A (en) * 2000-11-23 2002-06-03 Bavarian Nordic Res Inst As Modified vaccinia ankara virus variant
JP4801880B2 (ja) * 2002-04-19 2011-10-26 バヴァリアン・ノルディック・アクティーゼルスカブ 新生仔予防接種用変異ワクシニアウイルスアンカラ
US7501127B2 (en) * 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
KR101138067B1 (ko) * 2002-05-16 2012-04-24 버베리안 노딕 에이/에스 수두 바이러스 게놈내로 삽입된 상동 유전자를 발현하는 재조합 수두 바이러스
KR101044538B1 (ko) * 2002-09-05 2011-06-27 버베리안 노딕 에이/에스 무혈청 조건하에서 일차세포의 배양 및 바이러스의 증식방법
EP2363493B1 (en) * 2003-02-20 2012-11-14 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Novel insertion sites in pox vectors
GB2402391A (en) * 2003-06-04 2004-12-08 Oxxon Pharmaccines Ltd Fowlpox recombinant genome
WO2006052826A2 (en) * 2004-11-05 2006-05-18 The Government Of The United States Of America As Represented By The Secretary Methods for preparing cells and viruses
WO2006089690A1 (en) * 2005-02-23 2006-08-31 Bavarian Nordic A/S Use of a modified poxvirus for the rapid induction of immunity against a poxvirus or other infectious agents
EP2027271A4 (en) * 2006-05-19 2010-06-09 Glycofi Inc RECOMBINANT VECTORS
ES2396376T5 (es) * 2006-08-25 2017-05-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Sitios intergénicos entre genes conservados en el genoma del virus vaccinia de vaccinia Ankara modificado (MVA)
US20090098529A1 (en) * 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
EP2462930B1 (en) * 2006-11-09 2017-05-31 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using prime-boost approach
US8440202B2 (en) * 2006-11-09 2013-05-14 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using the prime-boost approach
EP2390340A3 (en) * 2007-01-30 2012-02-22 Transgene SA vector encoding Papillomavirus E1 and E2 polypeptides with reduced percentage of identity
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
TW200844231A (en) * 2007-05-15 2008-11-16 Transgene Sa Vectors for multiple gene expression
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
CA2681183A1 (en) * 2007-05-30 2008-12-11 Wyeth Raccoon poxvirus expressing genes of feline antigens
ES2608604T3 (es) * 2007-10-18 2017-04-12 Bavarian Nordic A/S Uso de MVA para tratar el cáncer de próstata
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
KR100894430B1 (ko) * 2008-11-11 2009-04-22 시스템디엔디(주) 초음파, 음향 및 온도변화를 이용한 밸브의 유체누설 측정장치 및 이를 이용한 유체누설 측정방법
CA2742247C (en) * 2008-11-21 2017-07-04 Bavarian Nordic A/S Vector comprising multiple homologous nucleotide sequences
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
AU2010305030A1 (en) 2009-10-08 2012-05-10 Bavarian Nordic A/S Generation of a broad T-cell response in humans against HIV
EP2488649B1 (en) 2009-10-16 2019-04-03 The U.S.A. as represented by the Secretary, Department of Health and Human Services Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
WO2011087839A1 (en) 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
US20130115234A1 (en) * 2010-03-26 2013-05-09 Emergent Product Development Gaithersburg,Inc. Ectodomains of Influenza Matrix 2 Protein, Expression System, and Uses Thereof
CA2802430C (en) 2010-07-20 2021-07-20 Bavarian Nordic A/S Method for harvesting poxvirus
US20120328649A1 (en) * 2010-09-23 2012-12-27 Baxter Healthcare S.A. Recombinant Viral Vectors and Methods for Inducing an Immune Response to Yellow Fever Virus
EP2627774B1 (en) 2010-10-15 2018-11-21 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) influenza vaccine
EA201301173A1 (ru) 2011-04-15 2015-08-31 Дженелюкс Корпорейшн Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования
WO2013083254A1 (en) 2011-12-09 2013-06-13 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
BR112014030436A2 (pt) 2012-06-05 2017-09-26 Univ Australian National método para induzir uma resposta imune antígeno-específico em um indivíduo, aumentar a avidez e o número de células imunitárias por um antígeno em um indivíduo, composição, método para a prevenção ou tratamento de uma infecção num indivíduo e de vacinação de um indivíduo contra uma infecção.
EP2879702B9 (en) 2012-08-01 2020-02-26 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
AU2013331328B2 (en) 2012-10-19 2018-05-31 Bavarian Nordic A/S Methods and compositions for the treatment of cancer
WO2014139587A1 (en) * 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
EP2968528B1 (en) * 2013-03-15 2022-02-23 Sementis Limited Immune modulation
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
KR101645642B1 (ko) 2014-10-16 2016-08-11 대한민국 Kvac１０３ 유래의 재조합 백시니아 바이러스
KR101623498B1 (ko) 2014-10-16 2016-05-24 대한민국 약독화 백시니아 바이러스주 kvac１０３
AU2016229408A1 (en) 2015-02-25 2017-09-14 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (ko) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
KR20160140075A (ko) * 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
WO2016202828A1 (en) 2015-06-15 2016-12-22 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN106591361A (zh) * 2015-10-20 2017-04-26 钱文斌 一种重组痘溶瘤病毒及其构建方法和应用
PL3402802T3 (pl) 2016-01-08 2023-06-05 Geovax, Inc. Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym
PL3407910T3 (pl) 2016-01-29 2022-08-16 Bavarian Nordic A/S Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni
WO2017136419A1 (en) * 2016-02-03 2017-08-10 Geovax Inc. Compositions and methods for generating an immune response to a flavivirus
CA3015650A1 (en) 2016-02-25 2017-08-31 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
CN109152827B (zh) 2016-02-25 2023-07-21 纪念斯隆凯特琳癌症中心 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
CN109922829A (zh) 2016-05-02 2019-06-21 扬森疫苗与预防公司 治疗性hpv疫苗组合
TWI728173B (zh) * 2016-08-19 2021-05-21 澳大利亞商賽門堤斯有限公司 病毒疫苗
US20200024610A1 (en) * 2016-09-30 2020-01-23 Monsanto Technology Llc Method for selecting target sites for site-specific genome modification in plants
EP3621646A4 (en) 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center USEFUL VACCINE VIRUS MUTANTS FOR ANTI-CANCER IMMUNOTHERAPY
US11229693B2 (en) * 2017-06-15 2022-01-25 Janssen Vaccines & Prevention B.V. Poxvirus vectors encoding HIV antigens, and methods of use thereof
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
CN112512569A (zh) * 2018-05-11 2021-03-16 希望之城 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途
JP2021523712A (ja) 2018-05-11 2021-09-09 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 安定性が改善された遺伝子組み換え組換えワクシニアアンカラ（ｒｍｖａ）ワクチン及びその調製方法
US12252702B2 (en) 2018-09-15 2025-03-18 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
CN111979204B (zh) * 2019-05-24 2023-10-13 杭州功楚生物科技有限公司 携带海绵凝集素基因的溶瘤痘苗病毒、构建方法及用途
BR112022009421A2 (pt) 2019-11-14 2022-10-25 Aelix Therapeutics S L Regimes de dosagem para vacinas
EP3842065A1 (en) * 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
TW202203966A (zh) * 2020-03-31 2022-02-01 澳大利亞商賽門蒂斯公司 用於防範ｃｏｖｉｄ－１９之以減毒的痘病毒載體為底質之疫苗
US20240033347A1 (en) 2022-07-08 2024-02-01 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
JPH0795956B2 (ja) * 1986-09-22 1995-10-18 京都大学長 ポックスウイルス由来発現制御領域
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5225336A (en) * 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5651972A (en) 1989-04-21 1997-07-29 University Of Florida Research Foundation, Inc. Use of recombinant swine poxvirus as a live vaccine vector
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US6893845B1 (en) * 1990-09-28 2005-05-17 Applied Molecular Evolution, Inc. Surface expression libraries of heteromeric receptors
DE69233158T2 (de) * 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
BE1004877A3 (fr) * 1991-05-27 1993-02-16 Solvay Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus.
FR2679249B1 (fr) * 1991-07-15 1993-11-26 Centre Nal Recherc Scientifique Souches de levure avec integration stable de genes heterologues.
AU670538B2 (en) 1991-07-26 1996-07-25 Virogenetics Corporation Infectious bursal disease virus recombinant poxvirus vaccine
ES2212795T3 (es) * 1991-08-26 2004-08-01 Baxter Healthcare S.A. Virus de la viruela de las aves de corral recombinante.
DE69229390T2 (de) * 1991-08-26 1999-11-11 Immuno Ag, Wien Direkt molekuläre Klonierung eines modifizierten Genoms eines Chordopocken-Virus
US5676950A (en) 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EP0753581A1 (en) * 1995-07-10 1997-01-15 Immuno Ag Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
DE19629828A1 (de) * 1996-07-24 1998-01-29 Bayer Ag Carbanilide
WO1998013500A2 (en) * 1996-09-24 1998-04-02 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
AUPP380598A0 (en) * 1998-05-29 1998-06-25 Commonwealth Scientific And Industrial Research Organisation Genetically manipulated entomopoxvirus
US6252871B1 (en) 1998-07-01 2001-06-26 Powerwave Technologies, Inc. Switchable combiner/splitter
US20040265324A1 (en) * 1999-03-23 2004-12-30 Cardosa Mary Jane Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
EP1180155B1 (en) * 1999-05-28 2008-10-29 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vector for integration of heterologous sequences into poxviral genomes
KR100880765B1 (ko) * 2000-03-14 2009-02-02 버베리안 노딕 에이/에스 변형된 백시니아 바이러스 안카라(ｍｖａ)의 변형 균주
CA2341356C (en) * 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
IL154169A0 (en) * 2000-08-29 2003-07-31 Wyeth Corp Packaging of positive-strand rna virus replicon particles
AU3163902A (en) * 2000-11-23 2002-06-03 Bavarian Nordic Res Inst As Modified vaccinia ankara virus variant
KR101138067B1 (ko) * 2002-05-16 2012-04-24 버베리안 노딕 에이/에스 수두 바이러스 게놈내로 삽입된 상동 유전자를 발현하는 재조합 수두 바이러스
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
EA012723B1 (ru) * 2002-11-25 2009-12-30 Бавариан Нордик А/С Рекомбинантный поксвирус, содержащий по меньшей мере два промотора ati вируса коровьей оспы, и его применение

Also Published As

Publication number Publication date
SI1407033T1 (sl) 2006-06-30
DK1506301T3 (da) 2014-07-21
US7964374B2 (en) 2011-06-21
CN102719408A (zh) 2012-10-10
US20050244428A1 (en) 2005-11-03
JP5777199B2 (ja) 2015-09-09
CN102703393A (zh) 2012-10-03
JP2011004755A (ja) 2011-01-13
JP4693092B2 (ja) 2011-06-01
CA2481799C (en) 2014-01-28
US20120135501A1 (en) 2012-05-31
US8034354B2 (en) 2011-10-11
US20090311746A1 (en) 2009-12-17
US8309326B2 (en) 2012-11-13
IL193088A (en) 2015-02-26
KR20040108809A (ko) 2004-12-24
DK1407033T3 (da) 2006-05-22
JP2005525823A (ja) 2005-09-02
CN1653184A (zh) 2005-08-10
ATE315660T1 (de) 2006-02-15
DE60303218T2 (de) 2006-09-14
EP2253709B1 (en) 2018-04-11
US20130243813A1 (en) 2013-09-19
IL164177A0 (en) 2005-12-18
EA200900180A1 (ru) 2009-08-28
ES2256776T3 (es) 2006-07-16
US20110250693A1 (en) 2011-10-13
EP1407033B1 (en) 2006-01-11
UA82479C2 (ru) 2008-04-25
PT1407033E (pt) 2006-05-31
CA2481799A1 (en) 2003-11-27
HK1076642A1 (en) 2006-01-20
KR20120002627A (ko) 2012-01-06
US20100173388A1 (en) 2010-07-08
US7550147B2 (en) 2009-06-23
EP1506301B1 (en) 2014-04-30
US8288125B2 (en) 2012-10-16
US8414900B2 (en) 2013-04-09
DE60303218D1 (de) 2006-04-06
AU2008255213A1 (en) 2009-01-08
AU2003236646A1 (en) 2003-12-02
NO336489B1 (no) 2015-09-07
AU2009200380B2 (en) 2009-10-01
US20060165727A1 (en) 2006-07-27
CN102199628A (zh) 2011-09-28
EP1506301A1 (en) 2005-02-16
PL372088A1 (en) 2005-07-11
CN1653183A (zh) 2005-08-10
KR20040108798A (ko) 2004-12-24
US20110053259A1 (en) 2011-03-03
EA200401507A1 (ru) 2005-06-30
PL216760B1 (pl) 2014-05-30
NO20045480L (no) 2004-12-16
AU2009200380C1 (en) 2010-03-11
HK1076836A1 (zh) 2006-01-27
KR101041691B1 (ko) 2011-06-14
AU2003242540A1 (en) 2003-12-02
NO20111324A1 (no) 2011-09-29
EP1407033A1 (en) 2004-04-14
US20120082696A1 (en) 2012-04-05
CA2481521C (en) 2012-04-17
AU2003236646B2 (en) 2009-01-15
EP2253709A1 (en) 2010-11-24
US8741308B2 (en) 2014-06-03
EA007811B1 (ru) 2007-02-27
CN100494388C (zh) 2009-06-03
NZ536502A (en) 2005-10-28
JP2010259446A (ja) 2010-11-18
BRPI0311178B1 (pt) 2020-11-17
AU2008255213B2 (en) 2011-10-06
CN1653183B (zh) 2012-07-25
US20100303856A1 (en) 2010-12-02
EA020230B1 (ru) 2014-09-30
KR101138067B1 (ko) 2012-04-24
IL193087A (en) 2012-10-31
BR0311178A (pt) 2005-03-29
MXPA04011194A (es) 2005-02-14
KR20100110901A (ko) 2010-10-13
NZ536501A (en) 2006-08-31
CN101831411A (zh) 2010-09-15
JP2005525822A (ja) 2005-09-02
US20110244574A1 (en) 2011-10-06
IL193087A0 (en) 2009-02-11
US20120178157A1 (en) 2012-07-12
JP4895505B2 (ja) 2012-03-14
MXPA04010713A (es) 2005-03-07
NO20044940L (no) 2004-11-12
CA2812019A1 (en) 2003-11-27
PL372093A1 (en) 2005-07-11
PL218318B1 (pl) 2014-11-28
WO2003097846A1 (en) 2003-11-27
IL193088A0 (en) 2009-02-11
BR0310051A (pt) 2005-02-15
US7338662B2 (en) 2008-03-04
EA012160B1 (ru) 2009-08-28
US8435543B2 (en) 2013-05-07
US20110053260A1 (en) 2011-03-03
BRPI0311178B8 (pt) 2021-05-25
KR101005630B1 (ko) 2011-01-05
NO334273B1 (no) 2014-01-27
US9109233B2 (en) 2015-08-18
IL164172A0 (en) 2005-12-18
AU2009200380A1 (en) 2009-02-19
WO2003097845A1 (en) 2003-11-27
CA2481521A1 (en) 2003-11-27
US20120039936A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
EA200401506A1 (ru) Рекомбинантный поксвирус, экспрессирующий гомологичные гены, встроенные в поксвирусный геном
WO2003029401A3 (en) Peptidoglycan recognition protein encoding nucleic acids and methods of use thereof
ATE228016T1 (de) Lebendvakzine zur behandlung von tumorerkrankungen
ATE268384T1 (de) Analog von haemophilus hin47 mit verminderter protease aktivität
DE60229962D1 (de) Verringerung der virulenz von mycobacterium tuberculosis und tuberkuloseschutz mittels inaktivierung des phop-gens
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
DE69635472D1 (de) Impfstoff gegen Geflügelkokzidose
DE60117053D1 (de) Herstellung rekombinanter künstlicher hefe-chromosome, welche das genom des humanen cytomegalovirus enthalten
EP0815233A4 (en) NEW CYTOKININE FROM BIRDS AND CODING GENETIC SEQUENCES THEREFOR
DE60332324D1 (de) Expec-spezifische proteine, entsprechende gene und ihre verwendungen
EP1090995A3 (en) Mycoplasma hyopneumoniae antigen MHP3, gene encoding it and uses thereof
UA90838C2 (ru) Рекомбинантный поксвирус, который экспрессирует гомологические гены, вставленные в поксвирусный геном
FR2809960B1 (fr) Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
AR046937A1 (es) Proteina nmb0928 y su uso en formulaciones farmaceuticas
MXPA03010910A (es) Metodo para generar microorganismos no virulentos a partir de patogenicos, mediante modificacion genetica permanente de su membrana bioligica, para producir vacunas.
NO20052525L (no) Spleisevariant av humant hypofyseveksthormon
WO2005054281A3 (es) Proteína nmb1125 y su uso en formulaciones farmaceuticas
Stram et al. Recombinant vaccines against IBDV
Rappuoli Annual Congress of the British Society for Immunology, 6-9 December 2005, Harrogate, UK. Abstracts
WO2005060328A3 (en) ENCODING NUCLEOTIDES OF GENES FROM THE CHROMOSOME OF THE BACTERIUM Mycoplasma hyopneumoniae, EXPRESSION AND ACTIVITY OF THE POLYNUCLEOTIDES AND THEIR APPLICATIONS
TH62970A (th) วัคซีนไวรัสโรคเบอร์ซาอักเสบติดต่อชนิดบรอดสเปคตรัม (broad spectrum)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM